Sign up to save your podcasts
Or
Share Experts Talk CLL #4 : Partnering with Patients for Treatment Initiation
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Experts Talk CLL #4 : Partnering with Patients for Treatment Initiation
A discussion between Dr. Peter Anglin and Dr. Carolyn Owen (Fall 2021)
In this episode, Dr. Anglin and Dr. Owen elaborate on discussions with patients that take place once a decision to initiate a particular treatment is made. They share their insights on how to reassure a patient while explaining potential side effects and monitoring requirements. Differences in conversations when a patient is treated with a BTK inhibitor vs venetoclax-based regimens are highlighted as well as the challenges associated with patient adherence.
Peter Anglin, MD, FRCPC, MBA Hematologist/Oncologist Physician Lead, Stronach Regional Cancer Centre Newmarket, ON
Carolyn Owen, MD, MDres(UK), FRCPC Hematologist, Tom Baker Cancer Centre Associate Professor, Division of Hematology & Hematological Malignancies, Tom Baker Cancer Centre, University of Calgary Local Principal Investigator, Tom Baker Cancer Centre
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.
View all episodes
By Various Topics on AML and CLL ManagementA discussion between Dr. Peter Anglin and Dr. Carolyn Owen (Fall 2021)
In this episode, Dr. Anglin and Dr. Owen elaborate on discussions with patients that take place once a decision to initiate a particular treatment is made. They share their insights on how to reassure a patient while explaining potential side effects and monitoring requirements. Differences in conversations when a patient is treated with a BTK inhibitor vs venetoclax-based regimens are highlighted as well as the challenges associated with patient adherence.
Peter Anglin, MD, FRCPC, MBA Hematologist/Oncologist Physician Lead, Stronach Regional Cancer Centre Newmarket, ON
Carolyn Owen, MD, MDres(UK), FRCPC Hematologist, Tom Baker Cancer Centre Associate Professor, Division of Hematology & Hematological Malignancies, Tom Baker Cancer Centre, University of Calgary Local Principal Investigator, Tom Baker Cancer Centre
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.